CN106727650A - A kind of Western medicine for treating Eaton agent pneumonia - Google Patents
A kind of Western medicine for treating Eaton agent pneumonia Download PDFInfo
- Publication number
- CN106727650A CN106727650A CN201611233819.8A CN201611233819A CN106727650A CN 106727650 A CN106727650 A CN 106727650A CN 201611233819 A CN201611233819 A CN 201611233819A CN 106727650 A CN106727650 A CN 106727650A
- Authority
- CN
- China
- Prior art keywords
- parts
- western medicine
- eaton agent
- agent pneumonia
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a kind of Western medicine for treating Eaton agent pneumonia, the Western medicine of the treatment Eaton agent pneumonia is according to the primary raw material of weight portion：8 15 parts of CZSC, 17 26 parts of purplestem privet leaf glycosides A, 8 15 parts of resveratrol, 11 16 parts of the Fen, fraxinellones of panax japonicus saponin IVa 6 10,15 20 parts of glycerine, 6 10 parts of taxol, 30 40 parts of yejuhua lactone, silver-colored 58 parts of linden glucoside, 7 16 parts of purpurin, 26 parts of karanjin, 59 parts of Tetrahydrocoptisine.Medicine of the present invention is strictly selected material composition according to the understanding mechanism of Eaton agent pneumonia, so as to reach the purpose of comprehensive rehabilitation, with rapid-action, effect stabilization, carry convenient to take, long-term taking and have no toxic side effect the characteristics of.
Description
Technical field
The present invention relates to a kind of field of medicine preparation, specifically a kind of Western medicine for treating Eaton agent pneumonia.
Background technology
Eaton agent pneumonia refers to various with antigenic organic dust, low-molecular-weight chemistry material etc. by sucking repeatedly
Other anaphylactogens, so as to the swollen property tuberculosis of the one group of diffusivity interstitial granulomatous dermatitis for causing.The generation of Eaton agent pneumonia is mainly and season
Property atmosphere pollution, indoor microorganism pollution it is relevant, the environment of etiology must be departed from before patient's treatment, make its breathing smooth simultaneously
And cause the material of pulmonary abnormalities reaction in air without other.Common anaphylactogen be mainly containing fungal spore, bacterial product,
The organic matter dust granules of animal protein or insect antigen, after suction anaphylactogen small number of patients occur pant, before runny nose etc.
Phase symptom, starts reaction symptom occur after 3~6 hours, be usually expressed as heating, dry cough, be short of breath, pectoralgia and anoxic, mouth
Lip, refer to toe end cyanosis etc., above-mentioned symptom reaches peak within 6~8 hours, and symptom disappears substantially within 24 hours, during breaking-out physical signs of lung with
Different during asthma attack, more without sound of stridulating, what is mainly heard is moist rales.Acute mycoplasma pneumonia is often behind contact allergy source
4~8 hours fall ill, performance symptom be heating, chilly, cough, expiratory dyspnea, apocleisis, nausea and vomiting, disengaging anaphylactogen it
Afterwards, symptom improves typically within a few houres, but recovers to need several weeks completely, and recurrent exerbation can cause pulmonary fibrosis；Subacute branch is former
The breaking-out of body symptoms of pneumonia is slow, and, to several weeks, the state of an illness person of continuing to develop needs hospitalization for cough and expiratory dyspnea last for days；Slowly
Property Eaton agent pneumonia patient, generally after sexuality is carried out occur expiratory dyspnea, cough, weak and Body weight loss up to the several months extremely
Several years, severe patient can develop into respiratory failure, therefore early diagnose and depart from the crucial institute that anaphylactogen is treated in time.Current medicine
Thing treatment is mainly long-term steroid, can alleviate and eliminate Acute Exacerbation Period symptom, and can prevent permanent lesion such as bronchus
The generation of expansion, irreversibility airway obstruction and pulmonary fibrosis.But more importantly treated and prevented since the initial stage, therefore
Needing a kind of medicine can play a part of the infringement that prevent and treat Eaton agent pneumonia and can reduce for human body PFT.
The content of the invention
It is an object of the invention to provide a kind of Western medicine for treating Eaton agent pneumonia, to solve to be proposed in above-mentioned background technology
Problem.
To achieve the above object, the present invention provides following technical scheme：
A kind of Western medicine for treating Eaton agent pneumonia, be according to the primary raw material of weight portion：CZSC 8-15 parts, purple stem female
17-26 parts of loyal glycosides A, resveratrol 8-15 parts, 11-16 parts of panax japonicus saponin IVa 6-10 Fen, fraxinellones, glycerine 15-20 parts,
Taxol 6-10 parts, yejuhua lactone 30-40 parts, silver-colored 5-8 parts of linden glucoside, purpurin 7-16 parts, karanjin 2-6 parts, four
5-9 parts of hydrogen coptisine.
As further scheme of the invention：The Western medicine of the treatment Eaton agent pneumonia, according to the primary raw material of weight portion
For：CZSC 9-13 parts, 19-22 parts of purplestem privet leaf glycosides A, resveratrol 10-12 parts, panax japonicus saponin IVa 7-9 Fen, Ash
Ketone 12-14 parts, glycerine 15-20 parts, taxol 6-10 parts, yejuhua lactone 34-37 parts, silver-colored 5-8 parts of linden glucoside, purpurin
7-16 parts, karanjin 3-4 parts, Tetrahydrocoptisine 5-9 parts.
As further scheme of the invention：The Western medicine of the treatment Eaton agent pneumonia, according to the primary raw material of weight portion
For：11 parts of CZSC, 21 parts of purplestem privet leaf glycosides A, 11 parts of resveratrol, 13 parts of the Fen, fraxinellones of panax japonicus saponin IVa 8, the third three
18 parts of alcohol, 8 parts of taxol, 36 parts of yejuhua lactone, silver-colored 7 parts of linden glucoside, 12 parts of purpurin, 4 parts of karanjin, the tetrahydrochysene coptis
8 parts of alkali.
A kind of preparation method of the Western medicine for treating Eaton agent pneumonia, concretely comprises the following steps：
First, in pharmaceutical grade clean area, by above-mentioned metering ratio weigh CZSC, purplestem privet leaf glycosides A, resveratrol,
Panax japonicus saponin IVa, fraxinellones, glycerine, taxol, yejuhua lactone, silver-colored linden glucoside, purpurin, karanjin, tetrahydrochysene are yellow
Even alkali, sieving, ultra-pure water is added after machinery mixing, is placed in pharmacy mixer, mixes 4-8min, controls RSD≤5%, mixing
Compressing tablet and low temperature drying afterwards, at 4-8 DEG C, packaging obtains final product the Western medicine for the treatment of Eaton agent pneumonia to temperature control.
As further scheme of the invention：Mix 6min in specific steps.
Compared with prior art, the beneficial effects of the invention are as follows：
Medicine of the present invention is strictly selected material composition according to the understanding mechanism of Eaton agent pneumonia, so as to reach comprehensively
The purpose of rehabilitation, with rapid-action, effect stabilization, carry convenient to take, long-term taking and have no toxic side effect the characteristics of.
Specific embodiment
Below in conjunction with the embodiment of the present invention, the technical scheme in the embodiment of the present invention is clearly and completely described,
Obviously, described embodiment is only a part of embodiment of the invention, rather than whole embodiments.Based in the present invention
Embodiment, the every other embodiment that those of ordinary skill in the art are obtained under the premise of creative work is not made, all
Belong to the scope of protection of the invention.
Embodiment 1
A kind of Western medicine for treating Eaton agent pneumonia, be according to the primary raw material of weight portion：8 parts of CZSC, purplestem privet leaf
In 17 parts of glycosides A, 8 parts of resveratrol, 11 parts of the Fen, fraxinellones of panax japonicus saponin IVa 6,15 parts of glycerine, 6 parts of taxol, chrysanthemum indicum
30 parts of ester, silver-colored 5 parts of linden glucoside, 7 parts of purpurin, 2 parts of karanjin, 5 parts of Tetrahydrocoptisine.
A kind of preparation method of the Western medicine for treating Eaton agent pneumonia, concretely comprises the following steps：
First, in pharmaceutical grade clean area, by above-mentioned metering ratio weigh CZSC, purplestem privet leaf glycosides A, resveratrol,
Panax japonicus saponin IVa, fraxinellones, glycerine, taxol, yejuhua lactone, silver-colored linden glucoside, purpurin, karanjin, tetrahydrochysene are yellow
Even alkali, sieving, ultra-pure water is added after machinery mixing, is placed in pharmacy mixer, mixes 4min, RSD≤5% is controlled, after mixing
Compressing tablet and low temperature drying, at 4 DEG C, packaging obtains final product the Western medicine for the treatment of Eaton agent pneumonia to temperature control.
Embodiment 2
A kind of Western medicine for treating Eaton agent pneumonia, be according to the primary raw material of weight portion：9 parts of CZSC, purplestem privet leaf
19 parts of glycosides A, 10 parts of resveratrol, 12 parts of the Fen, fraxinellones of panax japonicus saponin IVa 7,15 parts of glycerine, 6 parts of taxol, chrysanthemum indicum
34 parts of lactone, silver-colored 5 parts of linden glucoside, 7 parts of purpurin, 3 parts of karanjin, 5 parts of Tetrahydrocoptisine.
A kind of preparation method of the Western medicine for treating Eaton agent pneumonia, concretely comprises the following steps：
First, in pharmaceutical grade clean area, by above-mentioned metering ratio weigh CZSC, purplestem privet leaf glycosides A, resveratrol,
Panax japonicus saponin IVa, fraxinellones, glycerine, taxol, yejuhua lactone, silver-colored linden glucoside, purpurin, karanjin, tetrahydrochysene are yellow
Even alkali, sieving, ultra-pure water is added after machinery mixing, is placed in pharmacy mixer, mixes 4min, RSD≤5% is controlled, after mixing
Compressing tablet and low temperature drying, at 4 DEG C, packaging obtains final product the Western medicine for the treatment of Eaton agent pneumonia to temperature control.
Embodiment 3
A kind of Western medicine for treating Eaton agent pneumonia, be according to the primary raw material of weight portion：11 parts of CZSC, purplestem privet leaf
21 parts of glycosides A, 11 parts of resveratrol, 13 parts of the Fen, fraxinellones of panax japonicus saponin IVa 8,18 parts of glycerine, 8 parts of taxol, chrysanthemum indicum
36 parts of lactone, silver-colored 7 parts of linden glucoside, 12 parts of purpurin, 4 parts of karanjin, 8 parts of Tetrahydrocoptisine.
A kind of preparation method of the Western medicine for treating Eaton agent pneumonia, concretely comprises the following steps：
First, in pharmaceutical grade clean area, by above-mentioned metering ratio weigh CZSC, purplestem privet leaf glycosides A, resveratrol,
Panax japonicus saponin IVa, fraxinellones, glycerine, taxol, yejuhua lactone, silver-colored linden glucoside, purpurin, karanjin, tetrahydrochysene are yellow
Even alkali, sieving, ultra-pure water is added after machinery mixing, is placed in pharmacy mixer, mixes 6min, RSD≤5% is controlled, after mixing
Compressing tablet and low temperature drying, at 6 DEG C, packaging obtains final product the Western medicine for the treatment of Eaton agent pneumonia to temperature control.
Embodiment 4
A kind of Western medicine for treating Eaton agent pneumonia, be according to the primary raw material of weight portion：13 parts of CZSC, purplestem privet leaf
22 parts of glycosides A, 12 parts of resveratrol, 14 parts of the Fen, fraxinellones of panax japonicus saponin IVa 9,20 parts of glycerine, 10 parts of taxol, chrysanthemum indicum
37 parts of lactone, silver-colored 8 parts of linden glucoside, 16 parts of purpurin, 4 parts of karanjin, 9 parts of Tetrahydrocoptisine.
A kind of preparation method of the Western medicine for treating Eaton agent pneumonia, concretely comprises the following steps：
First, in pharmaceutical grade clean area, by above-mentioned metering ratio weigh CZSC, purplestem privet leaf glycosides A, resveratrol,
Panax japonicus saponin IVa, fraxinellones, glycerine, taxol, yejuhua lactone, silver-colored linden glucoside, purpurin, karanjin, tetrahydrochysene are yellow
Even alkali, sieving, ultra-pure water is added after machinery mixing, is placed in pharmacy mixer, mixes 8min, RSD≤5% is controlled, after mixing
Compressing tablet and low temperature drying, at 8 DEG C, packaging obtains final product the Western medicine for the treatment of Eaton agent pneumonia to temperature control.
Embodiment 5
A kind of Western medicine for treating Eaton agent pneumonia, be according to the primary raw material of weight portion：15 parts of CZSC, purplestem privet leaf
26 parts of glycosides A, 15 parts of resveratrol, 16 parts of the Fen, fraxinellones of panax japonicus saponin IVa 10,20 parts of glycerine, 10 parts of taxol, mother chrysanthemum
40 parts of flower lactone, silver-colored 8 parts of linden glucoside, 16 parts of purpurin, 6 parts of karanjin, 9 parts of Tetrahydrocoptisine.
A kind of preparation method of the Western medicine for treating Eaton agent pneumonia, concretely comprises the following steps：
First, in pharmaceutical grade clean area, by above-mentioned metering ratio weigh CZSC, purplestem privet leaf glycosides A, resveratrol,
Panax japonicus saponin IVa, fraxinellones, glycerine, taxol, yejuhua lactone, silver-colored linden glucoside, purpurin, karanjin, tetrahydrochysene are yellow
Even alkali, sieving, ultra-pure water is added after machinery mixing, is placed in pharmacy mixer, mixes 8min, RSD≤5% is controlled, after mixing
Compressing tablet and low temperature drying, at 8 DEG C, packaging obtains final product the Western medicine for the treatment of Eaton agent pneumonia to temperature control.
Pharmacology test
1st, chronic toxicity test
It is experiment with Western medicine obtained in the embodiment of the present invention 3, using gastric infusion mode, successive administration 2 times in 24h,
Per minor tick 8h, 400mg/kg doses are administered every time, daily accumulation medicine total amount reaches 800mg medicines/kg, it is clinical equivalent to people to use
100 times of amount.After administration in 7d, mouse activity, feed, excretion are normal, well-grown, and hair color light, its average weight is equal
Increase with the extension of experimental period.Every mouse of post mortem at 8d, visually observe the heart, liver, spleen, lung, kidney, brain, thymus gland,
Stomach, intestines etc. do not find color and paramophia, fail to measure median lethal dose (LD50).Result shows：Western medicine of the present invention without
Chronic toxicity.
2nd, long term toxicity test
It is experiment with Western medicine obtained in the embodiment of the present invention 3, using gastric infusion mode, Western medicine of the present invention is divided into low dose
Amount, middle dosage, three groups of high dose, the drug dose of each group is respectively 80,160,240mg medicines/kg/d, equivalent to clinical dosage
10,20,30 times.After gastric infusion 24 weeks, medicine of the present invention refers to the general status of animal, hematological indices, blood biochemical
Mark without obvious influence, Systematic anatomy, organ coefficient and histopathological examination also no abnormal pathological change.Drug withdrawal 2
Also substantially change is had no week.Result shows：Western medicine of the present invention does not find overt toxicity reaction and postpones in long term toxicity test
Toxic reaction.It can be seen that, Western medicine non-toxic reaction of the present invention, long-term prescription is safe and reliable.
It is obvious to a person skilled in the art that the invention is not restricted to the details of above-mentioned one exemplary embodiment, Er Qie
In the case of without departing substantially from spirit or essential attributes of the invention, the present invention can be in other specific forms realized.Therefore, no matter
From the point of view of which point, embodiment all should be regarded as exemplary, and be nonrestrictive, the scope of the present invention is by appended power
Profit requires to be limited rather than described above, it is intended that all in the implication and scope of the equivalency of claim by falling
Change is included in the present invention.
Moreover, it will be appreciated that although the present specification is described in terms of embodiments, not each implementation method is only wrapped
Containing an independent technical scheme, this narrating mode of specification is only that for clarity, those skilled in the art should
Specification an as entirety, the technical scheme in each embodiment can also be formed into those skilled in the art through appropriately combined
May be appreciated other embodiment.
Claims (5)
1. a kind of Western medicine for treating Eaton agent pneumonia, it is characterised in that the primary raw material according to weight portion is：CZSC 8-15
Part, 17-26 parts of purplestem privet leaf glycosides A, resveratrol 8-15 parts, 11-16 parts of panax japonicus saponin IVa 6-10 Fen, fraxinellones, glycerine
15-20 parts, taxol 6-10 parts, yejuhua lactone 30-40 parts, silver-colored 5-8 parts of linden glucoside, purpurin 7-16 parts, karanjin
2-6 parts, Tetrahydrocoptisine 5-9 parts.
2. it is according to claim 1 treatment Eaton agent pneumonia Western medicine, it is characterised in that the treatment Eaton agent pneumonia
Western medicine, be according to the primary raw material of weight portion：CZSC 9-13 parts, 19-22 parts of purplestem privet leaf glycosides A, resveratrol 10-12
Part, 12-14 parts of panax japonicus saponin IVa 7-9 Fen, fraxinellones, glycerine 15-20 parts, taxol 6-10 parts, yejuhua lactone 34-37
Part, silver-colored 5-8 parts, purpurin 7-16 parts, karanjin 3-4 parts, Tetrahydrocoptisine 5-9 parts of linden glucoside.
3. it is according to claim 1 and 2 treatment Eaton agent pneumonia Western medicine, it is characterised in that the treatment mycoplasma lung
Scorching Western medicine, be according to the primary raw material of weight portion：11 parts of CZSC, 21 parts of purplestem privet leaf glycosides A, 11 parts of resveratrol, bamboo
13 parts of the Fen, fraxinellones of section ginseng saponin I Va 8,18 parts of glycerine, 8 parts of taxol, 36 parts of yejuhua lactone, silver-colored 7 parts of linden glucoside, hydroxyl are alizarin
Careless 12 parts of element, 4 parts of karanjin, 8 parts of Tetrahydrocoptisine.
4. a kind of preparation method of the Western medicine for the treatment of Eaton agent pneumonia as described in claim 1-3 is any, it is characterised in that tool
Body step is：
First, in pharmaceutical grade clean area, CZSC, purplestem privet leaf glycosides A, resveratrol, ring are weighed by above-mentioned metering ratio
Ginseng saponin I Va, fraxinellones, glycerine, taxol, yejuhua lactone, silver-colored linden glucoside, purpurin, karanjin, the tetrahydrochysene coptis
Alkali, sieving, machinery adds ultra-pure water after mixing, place in pharmacy mixer, mixes 4-8min, RSD≤5% is controlled, after mixing
Compressing tablet and low temperature drying, at 4-8 DEG C, packaging obtains final product the Western medicine for the treatment of Eaton agent pneumonia to temperature control.
5. it is according to claim 4 treatment Eaton agent pneumonia Western medicine preparation method, it is characterised in that in specific steps
Mixing 6min.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611233819.8A CN106727650A (en) | 2016-12-28 | 2016-12-28 | A kind of Western medicine for treating Eaton agent pneumonia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611233819.8A CN106727650A (en) | 2016-12-28 | 2016-12-28 | A kind of Western medicine for treating Eaton agent pneumonia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106727650A true CN106727650A (en) | 2017-05-31 |
Family
ID=58921791
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611233819.8A Pending CN106727650A (en) | 2016-12-28 | 2016-12-28 | A kind of Western medicine for treating Eaton agent pneumonia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106727650A (en) |
-
2016
- 2016-12-28 CN CN201611233819.8A patent/CN106727650A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8394423B2 (en) | Compositions comprising apocynin, ginkgo and ginger and uses thereof | |
| Ghaemi et al. | The effectiveness of a traditional Persian medicine preparation in the treatment of chronic cough: A randomized, double-blinded, placebo-controlled clinical trial | |
| CN106727494A (en) | A kind of Western medicine for treating Eaton agent pneumonia | |
| CN106727650A (en) | A kind of Western medicine for treating Eaton agent pneumonia | |
| CN106511665A (en) | Pharmaceutical for treating allergic pneumonia | |
| CN104622854A (en) | Tablet containing ambroxol hydrochloride and salbutamol sulfate | |
| CN104586875B (en) | The preparation method of compound tilmicosin enteric coated particles | |
| CN106728287A (en) | A kind of Chinese and Western medicine combination for treating hylactic pneumonia and preparation method thereof | |
| CN106581032A (en) | Western medicine for treating hylactic pneumonia | |
| CN103417571A (en) | Composition for treating chicken mycoplasma respiratory infection and preparing method thereof | |
| WO2015131655A1 (en) | Use of fsk in preventing and treating chronic obstructive pulmonary disease | |
| Sun et al. | Combined exploration of the mechanism of Sang Xing Decoction in the treatment of smoke-induced acute bronchitis from protein and metabolic levels | |
| WO2015135372A1 (en) | Application of isoforskolin in preventing and treating chronic obstructive pulmonary disease | |
| CN113350442A (en) | Application of Bulbus Fritillariae Cirrhosae preparation in preventing and treating silicosis | |
| CN106619666A (en) | Pharmaceutical composition for treating swine dysentery | |
| HUE033992T2 (en) | Use of extracts from calendula for the treatment and prevention of disorders and impairments of cognitive and mental functions | |
| CN106727591A (en) | A kind of pharmaceutical composition for treating Streptococcus suis | |
| CN106619680A (en) | Western medicine for treating chronic respiratory failure | |
| CN106581031A (en) | Compound Western medicine for treating pertussis | |
| CN106822239A (en) | It is a kind of to treat Chinese and western medicinal composition of the infection of the upper respiratory tract and preparation method thereof | |
| CN106727642A (en) | A kind of children's antipyretic | |
| CN106692480A (en) | Western medicine for treating ventilation function failure | |
| CN105535532A (en) | Medicinal composition for treating community-acquired pneumonia | |
| CN106727643A (en) | A kind of Western medicine for treating bacterial pneumonia | |
| Luo et al. | Xiebai Zengye decoction improves respiratory function and attenuates inflammation in juvenile rats with postinfection cough via regulating ERK signaling pathway |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170531 |
|
| WD01 | Invention patent application deemed withdrawn after publication |